17.75
1.93%
-0.35
Dopo l'orario di chiusura:
16.87
-0.88
-4.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$18.10
Aprire:
$18.05
Volume 24 ore:
863.48K
Relative Volume:
0.50
Capitalizzazione di mercato:
$1.39B
Reddito:
$198.84M
Utile/perdita netta:
$-111.40M
Rapporto P/E:
-3.927
EPS:
-4.52
Flusso di cassa netto:
$-322.28M
1 W Prestazione:
-3.38%
1M Prestazione:
+16.55%
6M Prestazione:
+183.55%
1 anno Prestazione:
+154.66%
Travere Therapeutics Inc Stock (TVTX) Company Profile
Nome
Travere Therapeutics Inc
Settore
Industria
Telefono
888-969-7879
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-03-27 | Downgrade | Guggenheim | Buy → Neutral |
2023-12-05 | Aggiornamento | Citigroup | Neutral → Buy |
2023-11-20 | Iniziato | Citigroup | Neutral |
2023-09-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2023-09-21 | Downgrade | William Blair | Outperform → Mkt Perform |
2023-09-06 | Ripresa | Evercore ISI | Outperform |
2023-07-21 | Iniziato | JP Morgan | Overweight |
2023-06-07 | Ripresa | Piper Sandler | Neutral |
2023-05-22 | Iniziato | TD Cowen | Outperform |
2023-05-05 | Aggiornamento | Bryan Garnier | Sell → Neutral |
2023-03-01 | Iniziato | Guggenheim | Buy |
2023-02-21 | Aggiornamento | Wedbush | Neutral → Outperform |
2022-12-14 | Iniziato | Stifel | Hold |
2022-12-05 | Iniziato | Wells Fargo | Overweight |
2022-09-21 | Iniziato | Bryan Garnier | Sell |
2022-07-14 | Ripresa | Canaccord Genuity | Buy |
2022-03-31 | Iniziato | Piper Sandler | Overweight |
2022-02-28 | Iniziato | H.C. Wainwright | Buy |
2021-05-26 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com
Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St
Travere: Q3 Earnings Snapshot - The Washington Post
Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia
Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com
Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
TD Cowen reiterates Buy on Travere shares after PARASOL findings By Investing.com - Investing.com Canada
Semanteon Capital Management LP Purchases Shares of 36,699 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere presents data reinforcing clinical benefit of FILSPARI in IgAN - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 - The Manila Times
TSX Income Trust Index (RTCM) QuotePress Release - The Globe and Mail
(TVTX) Trading Report - Stock Traders Daily
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines
Travere Therapeutics (TVTX) to Release Quarterly Earnings on Thursday - MarketBeat
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money' - Yahoo Finance
Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High? - MSN
Travere Therapeutics to Report Third Quarter 2024 Financial Results - The Manila Times
Travere Therapeutics (NASDAQ:TVTX) Shares Gap UpTime to Buy? - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Upgraded at Wells Fargo & Company - MarketBeat
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings) - Benzinga
Wells Fargo raises Travere Therapeutics stock to Overweight rating By Investing.com - Investing.com Canada
State Street Corp's Strategic Reduction in Travere Therapeutics Holdings - GuruFocus.com
TVTX stock soars to 52-week high, hits $18.63 amid robust gains - Investing.com Australia
Travere Therapeutics (NASDAQ:TVTX) Hits New 1-Year HighHere's Why - MarketBeat
TVTX stock soars to 52-week high, hits $18.63 amid robust gains By Investing.com - Investing.com South Africa
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy - StockTitan
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PR Newswire
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views - Benzinga
Travere Therapeutics (NASDAQ:TVTX) Earns Sector Outperform Rating from Analysts at Scotiabank - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Investing in Travere Therapeutics Inc (TVTX) Is Getting More Attractive - Knox Daily
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 - The Manila Times
Travere Awaits FDA Ruling On Rare Kidney Disease Drug - RTTNews
Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Travere Therapeutics Inc Azioni (TVTX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
LYONS GARY A | Director |
Oct 04 '24 |
Sale |
14.73 |
40,000 |
589,101 |
51,000 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):